Gian D Pal1, Deborah Hall1, Bichun Ouyang1, Jessica Phelps1, Roy Alcalay2, Michael W Pauciulo3, William C Nichols3, Lorraine Clark4, Helen Mejia-Santana2, Lucia Blasucci1, Christopher G Goetz1, Cynthia Comella1, Amy Colcher5, Ziv Gan-Or6, Guy A Rouleau7, Karen Marder2. 1. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. 2. Department of Neurology and the Taub Institute, Columbia University Medical Center, New York, NY, USA. 3. Division of Human Genetics, Cincinnati Children's Hospital Medical Center and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 4. Department of Pathology and Cell Biology and the Taub Institute, Columbia University Medical Center, NY, New York, USA. 5. PRKNson's Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, Pennsylvania, USA. 6. Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. 7. Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada; The Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
Abstract
OBJECTIVE: In a cohort of patients with young-onset Parkinson's disease (PD), the authors assessed (1) the prevalence of genetic mutations in those who enrolled in deep brain stimulation (DBS) programs compared with those who did not enroll DBS programs and (2) specific genetic and clinical predictors of DBS enrollment. METHODS: Subjects were participants from 3 sites (Columbia University, Rush University, and the University of Pennsylvania) in the Consortium on Risk for Early Onset Parkinson's Disease (CORE-PD) who had an age at onset < 51 years. The analyses presented here focus on glucocerebrosidase (GBA), leucine-rich repeat kinase 2 (LRRK2), and parkin (PRKN) mutation carriers. Mutation carrier status, demographic data, and disease characteristics in individuals who did and did not enroll in DBS were analyzed. The association between mutation status and DBS placement was assessed in logistic regression models. RESULTS: Patients who had PD with either GBA, LRRK2, or PRKN mutations were more common in the DBS group (n = 99) compared with the non-DBS group (n = 684; 26.5% vs. 16.8%, respectively; P = 0.02). In a multivariate logistic regression model, GBA mutation status (odds ratio, 2.1; 95% confidence interval, 1.0-4.3; P = 0.05) was associated with DBS surgery enrollment. However, when dyskinesia was included in the multivariate logistic regression model, dyskinesia had a strong association with DBS placement (odds ratio, 3.8; 95% confidence interval, 1.9-7.3; P < 0.0001), whereas the association between GBA mutation status and DBS placement did not persist (P = 0.25). CONCLUSIONS: DBS populations are enriched with genetic mutation carriers. The effect of genetic mutation carriers on DBS outcomes warrants further exploration.
OBJECTIVE: In a cohort of patients with young-onset Parkinson's disease (PD), the authors assessed (1) the prevalence of genetic mutations in those who enrolled in deep brain stimulation (DBS) programs compared with those who did not enroll DBS programs and (2) specific genetic and clinical predictors of DBS enrollment. METHODS: Subjects were participants from 3 sites (Columbia University, Rush University, and the University of Pennsylvania) in the Consortium on Risk for Early Onset Parkinson's Disease (CORE-PD) who had an age at onset < 51 years. The analyses presented here focus on glucocerebrosidase (GBA), leucine-rich repeat kinase 2 (LRRK2), and parkin (PRKN) mutation carriers. Mutation carrier status, demographic data, and disease characteristics in individuals who did and did not enroll in DBS were analyzed. The association between mutation status and DBS placement was assessed in logistic regression models. RESULTS:Patients who had PD with either GBA, LRRK2, or PRKN mutations were more common in the DBS group (n = 99) compared with the non-DBS group (n = 684; 26.5% vs. 16.8%, respectively; P = 0.02). In a multivariate logistic regression model, GBA mutation status (odds ratio, 2.1; 95% confidence interval, 1.0-4.3; P = 0.05) was associated with DBS surgery enrollment. However, when dyskinesia was included in the multivariate logistic regression model, dyskinesia had a strong association with DBS placement (odds ratio, 3.8; 95% confidence interval, 1.9-7.3; P < 0.0001), whereas the association between GBA mutation status and DBS placement did not persist (P = 0.25). CONCLUSIONS: DBS populations are enriched with genetic mutation carriers. The effect of genetic mutation carriers on DBS outcomes warrants further exploration.
Authors: Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan B Bressman; William K Scott; Caroline Tanner; Susan Mickel; Howard Andrews; Cheryl Waters; Stanley Fahn; Lucien Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Karen Marder; Lorraine N Clark Journal: Arch Neurol Date: 2010-09
Authors: L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder Journal: Neurology Date: 2007-09-18 Impact factor: 9.910
Authors: Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia L Comella; Martha A Nance; Susan B Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin E Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Bradley Hiner; Haydeh Payami; Eric Molho; Stewart A Factor; John G Nutt; Carmen Serrano; Maritza Arroyo; Ruth Ottman; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Karen S Marder Journal: JAMA Neurol Date: 2014-01 Impact factor: 18.302
Authors: W M M Schuepbach; J Rau; K Knudsen; J Volkmann; P Krack; L Timmermann; T D Hälbig; H Hesekamp; S M Navarro; N Meier; D Falk; M Mehdorn; S Paschen; M Maarouf; M T Barbe; G R Fink; A Kupsch; D Gruber; G-H Schneider; E Seigneuret; A Kistner; P Chaynes; F Ory-Magne; C Brefel Courbon; J Vesper; A Schnitzler; L Wojtecki; J-L Houeto; B Bataille; D Maltête; P Damier; S Raoul; F Sixel-Doering; D Hellwig; A Gharabaghi; R Krüger; M O Pinsker; F Amtage; J-M Régis; T Witjas; S Thobois; P Mertens; M Kloss; A Hartmann; W H Oertel; B Post; H Speelman; Y Agid; C Schade-Brittinger; G Deuschl Journal: N Engl J Med Date: 2013-02-14 Impact factor: 91.245
Authors: Roy N Alcalay; Anat Mirelman; Rachel Saunders-Pullman; Ming-X Tang; Helen Mejia Santana; Deborah Raymond; Ernest Roos; Martha Orbe-Reilly; Tanya Gurevich; Anat Bar Shira; Mali Gana Weisz; Kira Yasinovsky; Maayan Zalis; Avner Thaler; Andres Deik; Matthew James Barrett; Jose Cabassa; Mark Groves; Ann L Hunt; Naomi Lubarr; Marta San Luciano; Joan Miravite; Christina Palmese; Rivka Sachdev; Harini Sarva; Lawrence Severt; Vicki Shanker; Matthew Carrington Swan; Jeannie Soto-Valencia; Brooke Johannes; Robert Ortega; Stanley Fahn; Lucien Cote; Cheryl Waters; Pietro Mazzoni; Blair Ford; Elan Louis; Oren Levy; Llency Rosado; Diana Ruiz; Tsvyatko Dorovski; Michael Pauciulo; William Nichols; Avi Orr-Urtreger; Laurie Ozelius; Lorraine Clark; Nir Giladi; Susan Bressman; Karen S Marder Journal: Mov Disord Date: 2013-10-15 Impact factor: 10.338
Authors: Aikaterina Angeli; Niccolo E Mencacci; Raquel Duran; Iciar Aviles-Olmos; Zinovia Kefalopoulou; Joseph Candelario; Sarah Rusbridge; Jennifer Foley; Priyanka Pradhan; Marjan Jahanshahi; Ludvic Zrinzo; Marwan Hariz; Nicholas W Wood; John Hardy; Patricia Limousin; Tom Foltynie Journal: Mov Disord Date: 2013-07-01 Impact factor: 10.338
Authors: Gian Pal; Graziella Mangone; Emily J Hill; Bichun Ouyang; Yuanqing Liu; Vanessa Lythe; Debra Ehrlich; Rachel Saunders-Pullman; Vicki Shanker; Susan Bressman; Roy N Alcalay; Priscilla Garcia; Karen S Marder; Jan Aasly; M Maral Mouradian; Samantha Link; Marc Rosenbaum; Sharlet Anderson; Bryan Bernard; Robert Wilson; Glenn Stebbins; William C Nichols; Marie-Laure Welter; Sepehr Sani; Mitra Afshari; Leo Verhagen; Rob M A de Bie; Tom Foltynie; Deborah Hall; Jean-Christophe Corvol; Christopher G Goetz Journal: Ann Neurol Date: 2022-01-25 Impact factor: 11.274
Authors: Suzanne Lesage; Ariane Lunati; Marion Houot; Sawssan Ben Romdhan; Fabienne Clot; Christelle Tesson; Graziella Mangone; Benjamin Le Toullec; Thomas Courtin; Kathy Larcher; Mustapha Benmahdjoub; Mohammed Arezki; Ahmed Bouhouche; Mathieu Anheim; Emmanuel Roze; François Viallet; François Tison; Emmanuel Broussolle; Murat Emre; Hasmet Hanagasi; Basar Bilgic; Meriem Tazir; Mouna Ben Djebara; Riadh Gouider; Christine Tranchant; Marie Vidailhet; Eric Le Guern; Olga Corti; Chokri Mhiri; Ebba Lohmann; Andrew Singleton; Jean-Christophe Corvol; Alexis Brice Journal: Ann Neurol Date: 2020-05-30 Impact factor: 10.422
Authors: Suzanne Lesage; Ariane Lunati; Marion Houot; Sawssan Ben Romdhan; Fabienne Clot; Christelle Tesson; Graziella Mangone; Benjamin Le Toullec; Thomas Courtin; Kathy Larcher; Mustapha Benmahdjoub; Mohamed Arezki; Ahmed Bouhouche; Mathieu Anheim; Emmanuel Roze; François Viallet; François Tison; Emmanuel Broussolle; Murat Emre; Hasmet Hanagasi; Basar Bilgic; Meriem Tazir; Mouna Ben Djebara; Riadh Gouider; Christine Tranchant; Marie Vidailhet; Eric Le Guern; Olga Corti; Chokri Mhiri; Ebba Lohmann; Andrew Singleton; Jean-Christophe Corvol; Alexis Brice Journal: Ann Neurol Date: 2020-07-28 Impact factor: 11.274
Authors: Carlo Alberto Artusi; Alok K Dwivedi; Alberto Romagnolo; Gian Pal; Marcelo Kauffman; Ignacio Mata; Dhiren Patel; Joaquin A Vizcarra; Andrew Duker; Luca Marsili; Binith Cheeran; Daniel Woo; Maria Fiorella Contarino; Leonard Verhagen; Leonardo Lopiano; Alberto J Espay; Alfonso Fasano; Aristide Merola Journal: JAMA Netw Open Date: 2019-02-01